Jacques P Tremblay

USPTO Granted Patents = 11 (Patent Applications = 7)

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 1.7

ph-index = 4

Forward Citations = 87(Granted Patents)

Location History:

Bernieres, CA (1998)
Bernières, CA (2002)
Berniere, CA (2007)
Stoneham, CA (2011 - 2014)
Quebec, CA (2014 - 2015)
Saint-Hubert, CA (2017)
Stoneham-Et-Tewkesbury, CA (2017 - 2019)

Company Filing History:

1 out of 832,891

Other

patents

Years Active: 1998-2019

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10323073 - CRISPR-based methods and products for increasing frataxin levels and uses thereof (2019-06-18),

2. 10280419 - Reduction of amyloid beta peptide production via modification of the APP gene using the CRISPR/Cas system (2019-05-07),

3. 9708414 - Methods and products for increasing frataxin levels and uses thereof (2017-07-18),

4. 9631783 - Lighting structure (2017-04-25),

5. 9139814 - Culture medium for myoblasts, precursors thereof and derivatives thereof (2015-09-22),

6. 8900572 - Myogenic differentiation of stem cells and uses thereof (2014-12-02),

7. 8802437 - Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations (2014-08-12),

8. 7887793 - Treatment of Duchenne muscular dystrophy with myoblasts expressing dystrophin and treated to block myostatin signaling (2011-02-15),

9. 7189391 - [object Object] (2007-03-13),

10. 6475993 - Treatment of hereditary diseases with gentamicin (2002-11-05),

11. 5833978 - Method of in vitro preconditioning healthy donor's myoblasts before (1998-11-10),

Title: Innovations and Contributions of Jacques P Tremblay

Introduction

Jacques P Tremblay is a notable inventor based in Canada, recognized for his significant contributions to the field of biotechnology. With a total of 11 patents to his name, Tremblay has made remarkable advancements in genetic engineering and therapeutic methods.

Latest Patents

Among his latest patents, Tremblay has developed CRISPR-based methods and products aimed at increasing frataxin levels. These methods include various products such as guide RNAs, recombinant fusion proteins, and frataxin targeting systems. These innovations are particularly relevant for treating Friedreich ataxia, a genetic disorder that affects coordination and movement. Another significant patent involves the reduction of amyloid beta peptide production through modifications of the APP gene using the CRISPR/Cas system. This technology has potential applications in treating Alzheimer's disease and age-related cognitive decline.

Career Highlights

Tremblay has had a distinguished career, working with prestigious institutions such as Université Laval. His work has focused on developing cutting-edge solutions to complex medical challenges, particularly in the realm of genetic disorders.

Collaborations

Throughout his career, Tremblay has collaborated with esteemed colleagues, including Pierre Chapdelaine and Joël Rousseau. These partnerships have fostered a collaborative environment that has led to innovative breakthroughs in biotechnology.

Conclusion

Jacques P Tremblay's contributions to the field of biotechnology through his patents and collaborations highlight his role as a leading inventor. His work continues to pave the way for advancements in genetic therapies and treatments for debilitating diseases.

This text is generated by artificial intelligence and may not be accurate.